Amycretin vs Semaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Zenagamtide, NNC0487-0111
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Key Comparison Insights
- Semaglutide is FDA approved, while Amycretin remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Amycretin (Human Trials).
Detailed Comparison
| Attribute | Amycretin | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Amycretin hits two appetite systems at once. The GLP-1 side slows stomach emptying, boosts insulin release after meals, and dampens appetite in the brain, the same biology behind semaglutide. The amylin side mimics a hormone your pancreas releases alongside insulin, which acts on the brainstem to make you feel full sooner and also curbs glucagon after eating. Novo combined these two signals in one molecule rather than mixing two drugs (which is what its CagriSema combination does). The bet is that the two pathways add together, giving more weight loss than either alone. That idea fits the early data, but it has not yet been tested head-to-head against semaglutide or tirzepatide in a large trial. | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. |
| Common Dosing | Trial doses of 1.25-40 mg once weekly (injection) Once weekly (injection) or once daily (tablet) | 1-2.4 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection once weekly, or oral tablet once daily (separate formulations) | Subcutaneous injection weekly, or oral (Rybelsus) |
| Typical Duration | 20-36 weeks in published trials; phase 3 runs longer | Long-term / chronic use |
| Best Time to Take | Same day each week (injection); trial protocols set timing for the tablet | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Two early trials were published in The Lancet in June 2025. In the subcutaneous phase 1b/2a trial (125 adults with overweight or obesity), the estimated weight loss assuming full adherence was 24.3% at 60 mg over 36 weeks and 22.0% at 20 mg over 36 weeks, versus roughly flat weight on placebo, with no plateau by the end of treatment. A separate phase 1 trial of the oral tablet (144 people, 12 weeks) showed up to 13.1% loss at the highest dose. In November 2025 Novo reported a 36-week phase 2 trial in 448 adults with type 2 diabetes: up to 14.5% weight loss with weekly injections (2.6% on placebo), up to 10.1% with the daily pill, and HbA1c drops of up to 1.8 points. Side effects were mostly gastrointestinal, dose-related, and mild to moderate. Novo moved both forms into phase 3; AMAZE 1 (weekly injection at 1.25, 5, 20 or 40 mg versus placebo, about 1,150 people without diabetes) is registered as NCT07339423 with completion expected in 2029. Honest caveats: the headline numbers come from small trials using an efficacy estimand that assumes everyone stayed on drug, and long-term safety is unknown. | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (New England Journal of Medicine, 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo. In the head-to-head STEP 8 trial it beat liraglutide (15.8% vs 6.4%). The weight tends to come back after stopping: in the STEP 1 extension, people regained about two-thirds of the lost weight within a year off the drug. The SELECT trial (17,604 adults with heart disease and overweight or obesity but no diabetes) cut major cardiovascular events by 20%, which is the basis of Wegovy's cardiovascular indication (March 2024), and the FLOW trial underpins the kidney indication. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. Oral versions are approved too. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. |
Frequently Asked Questions: Amycretin vs Semaglutide
What is the difference between Amycretin and Semaglutide?
Amycretin is a weight loss peptide that amycretin is novo nordisk's single-molecule agonist of both the glp-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the amaze program) in 2026. it is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks. Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Amycretin or Semaglutide?
Neither is universally "better" - the choice depends on your specific goals. Amycretin is typically used for weight loss purposes, while Semaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Amycretin and Semaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Amycretin and Semaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.